<?xml version="1.0" encoding="UTF-8"?>
<p id="p0045">Antivirals represent a class of drugs for which development is often focused on the singular outcome of limiting viral infection. However, side effects and potential off-label or secondary indications for the use of a drug are often only discovered after the drug is used with FDA approval. A prime example of a virus that is well studied with regards to antiviral therapy is HSV-1. HSV-1 frequently infects humans leading to diseases ranging from mild mucocutaneous lesions to life threatening infections, especially in elderly or immunocompromised patients (
 <xref rid="bib36" ref-type="bibr">Whitley and Roizman, 2001</xref>). HSV-1 is characterized by its ability to develop latency in neurons of sensory ganglia and lytic outbreaks that often require drug therapy (
 <xref rid="bib19" ref-type="bibr">Knickelbein et al., 2008</xref>). Although extensive research efforts have been made to unveil the mechanism of HSV-1 infection, new aspects of HSV-1 pathogenesis are frequently discovered (
 <xref rid="bib34" ref-type="bibr">Tognarelli et al., 2019</xref>; 
 <xref rid="bib29" ref-type="bibr">Sauerbrei, 2016</xref>; 
 <xref rid="bib16" ref-type="bibr">Johnston and Corey, 2016</xref>).
</p>
